Tonix Pharmaceuticals (TNXP) said Wednesday it submitted a new drug application to the US Food and Drug Administration for TNX-102 SL, an investigational drug in development to treat fibromyalgia.
TNX-102 SL showed a "statistically significant reduction" in pain linked with fibromyalgia in two phase 3 studies and was generally well tolerated, the company said.
The investigational drug was given fast track designation for fibromyalgia by the FDA in July, Tonix said.
Tonix said that, if the regulator accepts the new drug application for review, it expects a 2025 date for an approval decision, based on the Prescription Drug User Fee Act.
The company's shares were rising past 3% in recent trading.
Price: 0.15, Change: +0.01, Percent Change: +3.55
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。